Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymoglobulin Dose Comparison in Kidney Transplant
NCT03088280Phase 4Unknown
- Sponsor
- Hospital Geral de Fortaleza
- Start
- Jun 2015
- Primary completion
- Jan 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of antithymocyte globulin in kidney transplant rejection (2 arms), sponsored by Hospital Geral de Fortaleza. Primary endpoint: Acute Rejection at 1 year. Status: unknown.
02
Drugs
antithymocyte globulin
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT03088280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03088280.